One gene helps drive growth in two childhood brain tumor groups that lack targeted therapies

Targeting KDM2B or downstream protein complexes it recruits may exploit a vulnerability in high-risk medulloblastoma subgroups that currently lack targeted therapies, according to a study led by St. Jude Children's Research Hospital and Hopp Children's Cancer Center Heidelberg (KiTZ). The researchers found that Group 3 and Group 4 medulloblastomas depend on the protein KDM2B for growth and that removing it slowed tumor growth in preclinical models. The findings are published today in Nature Genetics.

≈